Parabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosedNI
Nextech Invest
Activity from announced rounds
Activity in this selectionJan 31, 2026 · Jan 1, 2026
Nextech Invest is the investment manager whose official portfolio includes Khartis, Parabilis and Circle Pharma.
Recorded funding activity
Circle develops macrocycle medicines. Khartis develops oral treatments for immune and chronic diseases, while Parabilis targets difficult cancer proteins. These are distinct drug-development programs within the recorded company history.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $305M 1 disclosed · full round size, not this investor’s share